Agenus Inc. (Nasdaq: AGEN) Q2 2025 Earnings Call | 08/27/2025

About this video

Agenus Inc., a clinical-stage biotechnology company, reported Q2 2025 revenue of $25.7 million, primarily from non-cash royalty revenue, slightly surpassing estimates. Despite revenue growth, the company posted a net loss of $56.4 million or $2.03 per share, an improvement from the prior year's $118.3 million loss. The results reflected effective cost management and ongoing capital infusion from strategic collaborations, including $91 million from Zydus Lifesciences to support clinical and regulatory efforts. Agenus continues progressing its immune-oncology and infectious disease programs, focusing on activating the immune system. The company aims to reduce net losses further through operational efficiencies and anticipates updating outlook and clinical milestones in upcoming calls. Analysts project improving earnings trends into 2026 amid sustained R&D investment and partnership expansions. About Inside Ticker: Inside Ticker delivers real-time financial news and detailed earnings summaries for investors and professionals. Visit www.insideticker.com. #Agenus #AGEN #Q22025 #Earnings #FinancialResults #Revenue #NetLoss #EPS #Biotechnology #ImmunoOncology #ClinicalStage #StrategicCollaboration #CostManagement #InvestorRelations #EarningsCall #NASDAQ #StockMarket #InsideTicker #FinancialPerformance #ResearchAndDevelopment